(VIANEWS) – SPBK1 NORD-NORGE (NONG.OL), LERØY SEAFOOD GP (LSG.OL), NAVAMEDIC (NAVA.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SPBK1 NORD-NORGE (NONG.OL)
28.5% sales growth and 13.71% return on equity
SpareBank 1 Nord-Norge provides banking services in Northern Norway. It operates through Retail Market, Corporate Market, Leasing, and Markets segments. The company offers mortgage, car, vehicle, and other loan related services. It also offers vehicle, home, travel, personal, and pet insurance services. In addition, the company provides various savings and pension related services, as well as debit and credit card services. Further, it offers financing, real estate leasing, agency, payment, and investment services. The company was founded in 1836 and is headquartered in Tromsø, Norway.
Earnings Per Share
As for profitability, SPBK1 NORD-NORGE has a trailing twelve months EPS of kr9.37.
PE Ratio
SPBK1 NORD-NORGE has a trailing twelve months price to earnings ratio of 10.39. Meaning, the purchaser of the share is investing kr10.39 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.71%.
Moving Average
SPBK1 NORD-NORGE’s worth is higher than its 50-day moving average of kr92.87 and higher than its 200-day moving average of kr91.42.
Sales Growth
SPBK1 NORD-NORGE’s sales growth is 63.1% for the ongoing quarter and 28.5% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 37.9%, now sitting on 4.37B for the twelve trailing months.
Yearly Top and Bottom Value
SPBK1 NORD-NORGE’s stock is valued at kr97.40 at 07:20 EST, below its 52-week high of kr103.60 and way higher than its 52-week low of kr78.10.
More news about SPBK1 NORD-NORGE.
2. LERØY SEAFOOD GP (LSG.OL)
10.7% sales growth and 15.65% return on equity
Lerøy Seafood Group ASA produces, processes, markets, sells, and distributes seafood products worldwide. It operates in three segments: Wildcatch; Farming; and Value-Added Processing, Sales and Distribution. The company offers smoked and gravad salmon, and trout products; farmed and wild catch whole fishes; fillets and portions; ready-to-eat and ready-to-cook products; fish blocks and cubes; breaded products; pre-fried fish burgers and patties; crustaceans and molluscs; seaweeds; and other products. Lerøy Seafood Group ASA markets its products primarily under the Norway Seafoods, Arctic Supreme, Fjord trout, Aurora Salmon, Fossen, Sea Eagle, Lerøy, and M?r brands to shops, restaurants, canteens, and hotels. The company was founded in 1899 and is headquartered in Bergen, Norway. Lerøy Seafood Group ASA is a subsidiary of Austevoll Seafood ASA.
Earnings Per Share
As for profitability, LERØY SEAFOOD GP has a trailing twelve months EPS of kr5.2.
PE Ratio
LERØY SEAFOOD GP has a trailing twelve months price to earnings ratio of 7.85. Meaning, the purchaser of the share is investing kr7.85 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.65%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 26.2%, now sitting on 28.09B for the twelve trailing months.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 24, 2023, the estimated forward annual dividend rate is 2.5 and the estimated forward annual dividend yield is 5.99%.
More news about LERØY SEAFOOD GP.
3. NAVAMEDIC (NAVA.OL)
10.5% sales growth and 22.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.75.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 22.17. Meaning, the purchaser of the share is investing kr22.17 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.97%.
Volume
Today’s last reported volume for NAVAMEDIC is 15930 which is 43.31% below its average volume of 28101.
Moving Average
NAVAMEDIC’s value is higher than its 50-day moving average of kr38.17 and higher than its 200-day moving average of kr35.69.
Sales Growth
NAVAMEDIC’s sales growth is 93.3% for the current quarter and 10.5% for the next.
Yearly Top and Bottom Value
NAVAMEDIC’s stock is valued at kr38.80 at 07:20 EST, way below its 52-week high of kr43.60 and way higher than its 52-week low of kr25.90.
More news about NAVAMEDIC.
4. SONAE (SON.LS)
10.5% sales growth and 10.11% return on equity
Sonae, SGPS, S.A. engages in retail, financial services, technology, shopping center, and telecommunications businesses. The company operates hypermarkets under the Continente brand; convenience supermarkets under the Continente Modelo and Continente Bom Dia brands; franchised supermarkets under the Meu Super brand; cafeteria under the Bagga brand; healthy food supermarkets and restaurants under the Go Natural brand; book shops and stationery under the Make Notes and Note! brands; health, well-being, and eye care centers under the Well´s brand; and dental and aesthetic medicine clinics under the Dr. Well's brand, as well as provides dog and cat products and services under the ZU brand. It also offers clothing, footwear, and accessories under the MO brand; baby and children clothing, footwear, and accessories, as well as childcare products under the Zippy and Losan brands; and jeans, clothing, and accessories under the Salsa brand. In addition, the company sells consumer electronics and entertainment products under the Worten brand; and mobile telecommunications products under the Worten Mobile brand, as well as develops real estate properties. Further, it offers payments, cards, personal loans, and insurance under the Universo brand; financing online purchases under the Universo Flex brand; and meal vouchers, gifting, and rewarding under the Da cards brand, as well as operates sports retail stores under JD, Sprinter, and Size? brand names. Additionally, the company provides telecommunication services to residential, personal, corporate, and wholesale markets; and investment management activities. It operates in Portugal, Spain, France, the United Kingdom, Germany, Italy, Romania, Brazil, Mexico, the Netherlands, and internationally. Sonae, SGPS, S.A. was founded in 1959 and is headquartered in Maia, Portugal. Sonae, SGPS, S.A. is a subsidiary of Efanor Investimentos SGPS, SA.
Earnings Per Share
As for profitability, SONAE has a trailing twelve months EPS of €0.14.
PE Ratio
SONAE has a trailing twelve months price to earnings ratio of 6.49. Meaning, the purchaser of the share is investing €6.49 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.11%.
More news about SONAE.
